Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Lung Cancer
Interventions: DRUG: OBI-833/OBI-821
Sponsor: OBI Pharma, Inc